In the past few years, the global RNAi market has shown several promising developments, and is expected to evolve greatly from its current state. According to a new research report by RNCOS, the competitive landscape in the flourishing RNAi industry is highly fragmented, with companies like Alnylam, Isis, and Tekmira providing an extensive platform for RNAi-related research and development, and Bioneer Corporation, Dharmacon and Life Technologies selling diverse RNAi products, such as vectors, reagents, kits and services. It is anticipated that the global RNAi market will expand stupendously at a CAGR of around 17% during 2011-2015.
Research Analysis & Highlights
The 105-page report, “Global RNAi Market Analysis”, provides an in-depth research and rational analysis of the current and expected status of the global RNAi industry, which has seen promising research and developments in the recent times. The research study provides an understanding of the RNAi market in key geographies, such as the US, Europe and Asia Pacific. RNAi applications in broad areas like therapeutics, drug discovery and development and agriculture have been discussed in detail in the report, which also informs about products and services of key market players. The therapeutic market is expected to evolve greatly in the future, and the study covers a detailed analysis on therapeutics in the development pipeline. The comprehensive research also elaborates key market trends and competitive landscape.
Some of the key findings of the report are:
- RNAi therapeutics will unfold the untapped future in the RNAi market.
- Fervent R&D and strong pipeline of drugs under development may reshape the RNAi sector.
- Drug discovery and development is a strong application for most players.
Some of our Related Reports are: